Co-Host: Vitaly Margulis, MD

At the conclusion of these activities, participants will be able to:

1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment.

2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.

CME Available: https://auau.auanet.org/node/26079

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma